Y-mAbs Therapeutics (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.
The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.
Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.
Shares of the company were down by nearly 6% in recent Friday trading.
Price: 7.01, Change: -0.38, Percent Change: -5.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。